Covid19CovExcNCT04649086

Muscular Rehabilitation by Eccentric Exercise After Severe COVID-19 Infection

A study testing Rehabilitation by Eccentric exercises and Rehabilitation by Concentric exercises in people with Covid19 and Sarcopenia, run by University Hospital, Clermont-Ferrand at 3 sites in France.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record

Search all trials

Trial summary

With the COVID-19 pandemic, the number of patients to be treated in rehabilitation increased . Hospitalization for severe infection can induce muscular atrophy and muscular dysfunction that persists for several months and rehabilitation capacities may be exceeded. Read more about this study

Who is it for?: Ages 18 to 80 years
Conditions the study is for: Covid19, Sarcopenia, Muscle Weakness
What is being tested?: Rehabilitation by Eccentric exercises and Rehabilitation by Concentric exercises
Could I receive a placebo?: No, everyone receives an active treatment
How many people: 60 participants
Where: 3 sitesFrance
Study dates: 5 Jun 2020to 7 Jan 2022
Phase: Interventional
Are there results?: None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 18 to 80 years
All sexes
No healthy volunteers
Adult, Older adult

Who may be able to join

Male or female, 18 to 80 years old
Diagnosed for SARS-CoV-2 infection (COVID-19) requiring a rehabilitation program at least 1 month after the hospitalization
Autonomy in daily life activities 1 month after diagnosis
Able to walk for 6 min (discontinuous walking possible)
Giving informed written consent to participate in the study
Health insurance coverage

Who cannot join

Cardiovascular or respiratory contraindication to the rehabilitation program
Difficulty to perform an eccentric exercise on a seated ergometer
Pregnant or breastfeeding
Under guardianship, curatorship or deprived of liberty
Taking antivitamin K anticoagulation (muscle biopsy)
Refusal to participate

Trial locations and contacts

3 sites in 1 country.

France3 sites

CHU de Clermont-Ferrand
Clermont-Ferrand, 63000
CHU de Dijon
Dijon, 21000
CHU de Saint-Etienne
Saint-Etienne, 42000

Other trials in France

About this study

Official title: Muscular Rehabilitation by Eccentric Exercise After Severe COVID-19 Infection: Research Protocol for Randomized Controlled Trial (CovExc)

With the COVID-19 pandemic, the number of patients to be treated in rehabilitation increased .

Hospitalization for severe infection can induce muscular atrophy and muscular dysfunction that persists for several months and rehabilitation capacities may be exceeded.

Exercises in eccentric mode could be performed, inducing greater muscular hypertrophy, muscle strength, power and speed than concentric exercises.

The goal of this study was to compare functional recovery at 2 months after a training program in eccentric and concentric mode after severe COVID-19.

An effective rehabilitation could help reduce costs and duration of care.

Read the detailed description

This is a prospective, open, controlled randomized study (2 x 60 individuals) performed in 3 centers. Participants will perform 24 exercise sessions on cycloergometer (3 sessions/week, 8 weeks). The experimental group (eccentric) will perform 5 habituation sessions: the initial power of the exercise will be set to 10 Watts and then increased by 10% each session, depending on the muscle tolerance. The training power must correspond to 3 times that of the control group to obtain a similar metabolic stimulation. The control group (concentric) will perform exercise training at an intensity of 60% of the reserve heart rate determined during an initial cardiorespiratory test. The primary outcome will be the change in distance covered during the 6-min walk test between the initial assessment and month 2. Secondary outcomes will include study of sarcopenia, muscle strength, general and muscular fatigue, quality of life, blood metabolomic data, ex vitro data for mitochondrial and histo-biochemical functionality from muscle biopsies of the Vastus Lateralis.

Conditions: Covid19, Sarcopenia, Muscle Weakness
Being tested: Rehabilitation by Eccentric exercises, Rehabilitation by Concentric exercises
Keywords: Covid19, Sarcopenia, Muscle Weakness, Eccentric exercises, Rehabilitation
Medical subject headings: COVID-19, Sarcopenia, Muscle Weakness

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Rehabilitation by Eccentric exercisesOther
Participants will perform 24 exercises sessions (30 minutes) with cycloergometer in eccentric mode (while resisting against self-paced pedaling), inducing a greater muscular hypertrophy as compared with concentric mode, the mechanical stimulation being 3 to 4 times greater at the same level metabolic stimulation.
Rehabilitation by Concentric exercisesOther
The control group (concentric) will perform exercise training at an intensity of 60% of the reserve heart rate determined during an initial cardiorespiratory test. The power will be adjusted weekly to stay within the target heart rate range.

Study groups in NCT04649086
Study group	Role	What they receive
Eccentric group	Experimental	The experimental group (eccentric) will perform 5 habituation sessions: the initial power of the exercise will be set to 10 Watts and then increased by 10% each session, depending on the muscle tolerance. The training power must correspond to 3 times that of the control group to obtain a similar metabolic stimulation and will be adapted according to the pain felt at the end of the session. Receives: Other: Rehabilitation by Eccentric exercises
Concentric group	Active comparator	The control group (concentric) will perform exercise training at an intensity of 60% of the reserve heart rate determined during an initial cardiorespiratory test. The power will be adjusted weekly to stay within the target heart rate range. Receives: Other: Rehabilitation by Concentric exercises

What is being measured

The primary outcome is the main question the study is designed to answer.

Functional walking capacity
Average change from baseline walking capacity measured by the 6-minutes walk test (6MWT), expressed in meters. All patients will be asked to cover the longest distance over a 30-meters distance in 6 min with or without stopping and with standardized verbal encouragements according to standard recommendations; to take into account a learning effect, the test will be performed twice, with the longer distance retained, expressed in meters. To prevent adverse effect, pulsed oxygen saturation (% of pSO²) and heart rate (heartbeat per minute) will be monitored continuously throughout the test by using a digital oximeter.
Measured: Day 0, Month 1, Month 2 and Month 6

Secondary outcomes (19)

Evaluating of lower extremity functioning by Short Physical Performance Battery (SPPB) score
this test consists of assessing balance in a standing position, lifting from a chair (5 stand to-sit repetitions) and measuring 4-m walking speed (20). The patient walks 4 m at a normal and comfortable speed. The "test zone" (4 m) is preceded by an "acceleration zone" (1 m) and is followed by a "deceleration zone" (1 m). The assessor starts and stops the timing when the subject's foot meets the ground when entering and leaving the "test area", respectively.
Measured: Day 0, Month 2 and Month 6
Evaluating the maximum muscle strength of the quadriceps by Quadriceps Isometric Maximum Strength (QIMS) test
maximum muscle strength of the quadriceps, on the dominant limb, will be measured on a bench: - Strength during isometric contraction (at 90° knee flexion) - Standardized position with the arms crossed on the chest, the absence of back support during the measurement and the maintenance of the hips and the contralateral leg to avoid any compensating movement Three reproducible measurements (±10%) will be taken at 1-min intervals, with the highest value retained.
Measured: Day 0, Month 2
Evaluating the fatigability of the quadriceps by Quadriceps Intermittent Fatigue (QIF) test
this test consists of performing 10 knee extensions at 10% QIMS, then gradually increasing the load (10% by 10%) until exhaustion (cannot perform the movement 2 consecutive times). The value retained is the last level (% QIMS) performed.
Measured: Day 0, Month 2
Evaluating the global fatigability by Modified Fatigue Impact Scale (MFIS)
this scale explores cognitive (10 items), physical (9 items) and psychosocial (2 items) fatigue. The MFIS included 21 items with a total score ranging from 0 to 84 with higher scores indicating a greater impact of quality of life.
Measured: Day 0, Month 2 and Month 6
Evaluating functional capacities with EuroQol - 5 Dimensions (EQ-5D) questionnaire
This questionnaire explores 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The EQ-5D-5L included 5 items independently scored from 1 to 5 (higher scores indicating a greater impact)and a 0-100 visual analogic scale exploring general health (0 means the worst heath patient can imagine, 100 means the best health patient can imagine).
Measured: Day 0, Month 2 and Month 6
Evaluating the handgrip strength by standard handgrip strength test
measurement is in 90° elbow flexion, wrist in neutral position. Three reproducible measurements (± 10%) will be taken at 1-min intervals, with the highest value retained.
Measured: Day 0, Month 2
Metabolomic Profile
Plasma metabolome profile assessed by variation of number of blood metabolites. Changes from baseline to post-training intervention in plasma metabolome profile will be compared between excentric and concentric exercise groups.
Measured: Day 0, Month 2 (post-training)
Cross sectional area measurement
Biopsy from the Vastus lateralis will be performed and the variation of cross sectional area measurement of muscle fibers (µm2) will be analysed and compared between excentric and concentric exercise groups from baseline to post-training intervention.
Measured: Day 0, Month 2 (post-training)
Capillary to fibre ratio.
Biopsy from the Vastus lateralis will be performed and the capillarization (variation of capillary to fiber ratio) will be analysed.
Muscle adapations from baseline to post-training intervention will be compared between excentric and concentric exercise groups.
Measured: Day 0, Month 2 (post-training)
Satellite cell number
Biopsy from the Vastus lateralis will be performed and the evolution of number of satellite cell per muscle fiber will be analysed and compared between excentric and concentric exercise groups from baseline to post-training intervention.
Measured: Day 0, Month 2 (post-training)
Neuromuscular activation
Electrophsyiological stimulation of the quadriceps for the measurement of the neuromuscular activation before, during and after the QIF test. During this test, we measure maximal M-wave, contraction time and torque and the percentage of neuromuscular activation. Neuromuscular activation will be analysed and compared between excentric and concentric exercise groups from baseline to post-training intervention.
Measured: Day 0, Month 2 (post-training)
Quadriceps muscular Oxygen Tissue Saturation
An infrared spectroscopy device is localized on the anterior part of the quadriceps. The device measures hemoglobin and desoxyhemoglobin concentration under the placement area. This measure is performed, before, during and after the QIF test. During this test, we measure the hemoglobin and desoxyhemoglobin concentration as well as the tissue saturation index.Quadriceps muscular Oxygen Tissue Saturation will be analysed and compared between excentric and concentric exercise groups from baseline to post-training intervention.
Measured: Day 0, Month 2 (post-training)
O2 uptake Efficiency during walk test
A gaz exchange device records the O2 uptake during the 6 minutes walk test. The O2 uptake efficiency was defined as the volume of O2 per meter used by the participant.
An infrared spectroscopy device is localized on the anterior part of the quadriceps. O2 uptake Efficiency during walk test will be analysed and compared between excentric and concentric exercise groups from baseline to post-training intervention.
Measured: Day 0, Month 2 (post-training)
Creatine Kinase (CPK)
A blood sample collection to measure the CPK concentration.
Measured: Day 0
Creatine Kinase (CPK)
A blood sample collection to measure the CPK concentration.
Measured: Day 7 (post-training)
Creatine Kinase (CPK)
A blood sample collection to measure the CPK concentration.
Measured: Month 2 (post-training)
C-reactive protein (CRP)
A blood sample collection to measure CRP concentration.
Measured: Day 0
C-reactive protein (CRP)
A blood sample collection to measure CRP concentration.
Measured: Day 7 (post-training)
C-reactive protein (CRP)
A blood sample collection to measure CRP concentration.
Measured: Month 2 (post-training)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

5 Jun 20207 Jan 2022

First posted2 Dec 2020
Study start5 Jun 2020
Primary completion7 Jan 2022
Study completion7 Jan 2022

Why it stopped: Stop premature due to futility

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Publications (8)Papers the sponsor has linked to this study.
Other trials for Covid19Studies of the same condition, open and under way.
More trials run by University Hospital, Clermont-FerrandThe sponsor's other registered studies.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase N/A
Primary purpose: Treatment
Allocation: Randomised
Intervention model: Parallel groups
Model description: All included participants will be randomly assigned (1:1) using the REDCap software, , at the experimental group or the control group. Participants will perform 24 exercise sessions on cycloergometer (3 sessions/week, 8 weeks). The experimental group (eccentric) will perform 5 habituation sessions: the initial power of the exercise will be set to 10 Watts and then increased by 10% each session, depending on the muscle tolerance. The training power must correspond to 3 times that of the control group to obtain a similar metabolic stimulation. The control group (concentric) will perform exercise training at an intensity of 60% of the reserve heart rate determined during an initial cardiorespiratory test.
Masking: None (open label)
Enrolment: 60 participants (actual)

IDs, dates and publications

ClinicalTrials.gov ID: NCT04649086
Sponsor's protocol ID: PHRCI 2020 COSTE (CovExc)
Other IDs: 2020-A01201-38
Acronym: CovExc
Status last verified: Aug 2026
First submitted: 29 Sep 2020
Last updated: 5 Aug 2026
Results posted: No
Data monitoring committee: No
FDA-regulated drug: No
FDA-regulated device: No

Publications

Zhang P, Li J, Liu H, Han N, Ju J, Kou Y, Chen L, Jiang M, Pan F, Zheng Y, Gao Z, Jiang B. Long-term bone and lung consequences associated with hospital-acquired severe acute respiratory syndrome: a 15-year follow-up from a prospective cohort study. Bone Res. 2020 Feb 14;8:8. doi: 10.1038/s41413-020-0084-5. eCollection 2020.
PubMed 32128276
Puthucheary ZA, Rawal J, McPhail M, Connolly B, Ratnayake G, Chan P, Hopkinson NS, Phadke R, Dew T, Sidhu PS, Velloso C, Seymour J, Agley CC, Selby A, Limb M, Edwards LM, Smith K, Rowlerson A, Rennie MJ, Moxham J, Harridge SD, Hart N, Montgomery HE. Acute skeletal muscle wasting in critical illness. JAMA. 2013 Oct 16;310(15):1591-600. doi: 10.1001/jama.2013.278481.
PubMed 24108501
Connolly B, Salisbury L, O'Neill B, Geneen L, Douiri A, Grocott MP, Hart N, Walsh TS, Blackwood B. Exercise rehabilitation following intensive care unit discharge for recovery from critical illness: executive summary of a Cochrane Collaboration systematic review. J Cachexia Sarcopenia Muscle. 2016 Dec;7(5):520-526. doi: 10.1002/jcsm.12146. Epub 2016 Sep 16.
PubMed 27891297
van Zanten ARH, De Waele E, Wischmeyer PE. Nutrition therapy and critical illness: practical guidance for the ICU, post-ICU, and long-term convalescence phases. Crit Care. 2019 Nov 21;23(1):368. doi: 10.1186/s13054-019-2657-5.
PubMed 31752979
Wu Y, Xu X, Chen Z, Duan J, Hashimoto K, Yang L, Liu C, Yang C. Nervous system involvement after infection with COVID-19 and other coronaviruses. Brain Behav Immun. 2020 Jul;87:18-22. doi: 10.1016/j.bbi.2020.03.031. Epub 2020 Mar 30.
PubMed 32240762
Bailey P, Thomsen GE, Spuhler VJ, Blair R, Jewkes J, Bezdjian L, Veale K, Rodriquez L, Hopkins RO. Early activity is feasible and safe in respiratory failure patients. Crit Care Med. 2007 Jan;35(1):139-45. doi: 10.1097/01.CCM.0000251130.69568.87.
PubMed 17133183
Needham DM. Mobilizing patients in the intensive care unit: improving neuromuscular weakness and physical function. JAMA. 2008 Oct 8;300(14):1685-90. doi: 10.1001/jama.300.14.1685.
PubMed 18840842
Cormier C, Lanhers C, Rannou F, Grolier M, Pelletier Visa M, Feasson L, Ornetti P, Gouteron A, Richard R, Costes F, Pereira B, Coudeyre E. Impact of eccentric exercise on walking functional capacity after severe COVID-19: randomized, controlled open-label trial. Ann Phys Rehabil Med. 2026 Jun;69(5):102125. doi: 10.1016/j.rehab.2026.102125. Epub 2026 Apr 20.
PubMed 42019312

Want to know more?

The sponsor has not listed a contact. The official record may have more details.

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See locations

Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Active, not recruitingPhase 1
A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults
COVID-19
Active, not recruiting
Intervention to Address Disparate Mental Health Consequences of COVID-19 Pandemic on Latinx and African Newcomers
Mental Health Issue, Mental Health Disorder
Recruiting
Home-Based Exercise Tele-Rehabilitation After COVID-19
Post SARS-CoV2 (COVID-19)
Not yet recruitingPhase 1
A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 Vaccine
COVID -19

All Covid19 trials

Study at a glance

From the registry record, last updated by the sponsor on 5 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: Muscular Rehabilitation by Eccentric Exercise After Severe COVID-19 Infection: Research Protocol for Randomized Controlled Trial (CovExc)
ClinicalTrials.gov ID: NCT04649086
Acronym / sponsor ID: CovExc / PHRCI 2020 COSTE (CovExc)
Conditions: Covid19, Sarcopenia, Muscle Weakness
Keywords: Covid19, Sarcopenia, Muscle Weakness, Eccentric exercises, Rehabilitation
Study type: Interventional
Recruitment status: TerminatedReason stopped: Stop premature due to futility
Enrolment: 60 participants (actual)
Lead sponsor: University Hospital, Clermont-FerrandUniversity, hospital or other
Collaborators: GIRCI Auvergne Rhone-Alpes, Ministry of Health, France
Study start: 5 Jun 2020 (actual)
Primary completion: 7 Jan 2022 (actual)
Study completion: 7 Jan 2022 (actual)
First posted: 2 Dec 2020 (actual)
Results: Not posted in the source record

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

With the COVID-19 pandemic, the number of patients to be treated in rehabilitation increased .

Hospitalization for severe infection can induce muscular atrophy and muscular dysfunction that persists for several months and rehabilitation capacities may be exceeded.

Exercises in eccentric mode could be performed, inducing greater muscular hypertrophy, muscle strength, power and speed than concentric exercises.

The goal of this study was to compare functional recovery at 2 months after a training program in eccentric and concentric mode after severe COVID-19.

An effective rehabilitation could help reduce costs and duration of care.

Detailed description

Study design

Primary purpose: Treatment
Allocation: Randomised
Intervention model: Parallel groups
Masking: None (open label)
Number of arms: 2
Model description: All included participants will be randomly assigned (1:1) using the REDCap software, , at the experimental group or the control group. Participants will perform 24 exercise sessions on cycloergometer (3 sessions/week, 8 weeks). The experimental group (eccentric) will perform 5 habituation sessions: the initial power of the exercise will be set to 10 Watts and then increased by 10% each session, depending on the muscle tolerance. The training power must correspond to 3 times that of the control group to obtain a similar metabolic stimulation. The control group (concentric) will perform exercise training at an intensity of 60% of the reserve heart rate determined during an initial cardiorespiratory test.

Arm	Type	Receives
Eccentric group	Experimental	Other: Rehabilitation by Eccentric exercisesThe experimental group (eccentric) will perform 5 habituation sessions: the initial power of the exercise will be set to 10 Watts and then increased by 10% each session, depending on the muscle tolerance. The training power must correspond to 3 times that of the control group to obtain a similar metabolic stimulation and will be adapted according to the pain felt at the end of the session.
Concentric group	Active comparator	Other: Rehabilitation by Concentric exercisesThe control group (concentric) will perform exercise training at an intensity of 60% of the reserve heart rate determined during an initial cardiorespiratory test. The power will be adjusted weekly to stay within the target heart rate range.

Who may qualify

Ages: 18 to 80 years
Sex: All
Healthy volunteers: Not accepted
Age groups: Adult, Older adult

Key inclusion criteria (6 listed)

Male or female, 18 to 80 years old
Diagnosed for SARS-CoV-2 infection (COVID-19) requiring a rehabilitation program at least 1 month after the hospitalization
Autonomy in daily life activities 1 month after diagnosis
Able to walk for 6 min (discontinuous walking possible)
Giving informed written consent to participate in the study

Key exclusion criteria (6 listed)

Cardiovascular or respiratory contraindication to the rehabilitation program
Difficulty to perform an eccentric exercise on a seated ergometer
Pregnant or breastfeeding
Under guardianship, curatorship or deprived of liberty
Taking antivitamin K anticoagulation (muscle biopsy)

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
Rehabilitation by Eccentric exercisesParticipants will perform 24 exercises sessions (30 minutes) with cycloergometer in eccentric mode (while resisting against self-paced pedaling), inducing a greater muscular hypertrophy as compared with concentric mode, the mechanical stimulation being 3 to 4 times greater at the same level metabolic stimulation.	Other	Eccentric group
Rehabilitation by Concentric exercisesThe control group (concentric) will perform exercise training at an intensity of 60% of the reserve heart rate determined during an initial cardiorespiratory test. The power will be adjusted weekly to stay within the target heart rate range.	Other	Concentric group

Primary outcome

Functional walking capacity
Time frame: Day 0, Month 1, Month 2 and Month 6
Average change from baseline walking capacity measured by the 6-minutes walk test (6MWT), expressed in meters. All patients will be asked to cover the longest distance over a 30-meters distance in 6 min with or without stopping and with standardized verbal encouragements according to standard recommendations; to take into account a learning effect, the test will be performed twice, with the longer distance retained, expressed in meters. To prevent adverse effect, pulsed oxygen saturation (% of pSO²) and heart rate (heartbeat per minute) will be monitored continuously throughout the test by using a digital oximeter.

19 secondary outcomes

Evaluating of lower extremity functioning by Short Physical Performance Battery (SPPB) score
Time frame: Day 0, Month 2 and Month 6
Evaluating the maximum muscle strength of the quadriceps by Quadriceps Isometric Maximum Strength (QIMS) test
Time frame: Day 0, Month 2
Evaluating the fatigability of the quadriceps by Quadriceps Intermittent Fatigue (QIF) test
Time frame: Day 0, Month 2
Evaluating the global fatigability by Modified Fatigue Impact Scale (MFIS)
Time frame: Day 0, Month 2 and Month 6
Evaluating functional capacities with EuroQol - 5 Dimensions (EQ-5D) questionnaire
Time frame: Day 0, Month 2 and Month 6
Evaluating the handgrip strength by standard handgrip strength test
Time frame: Day 0, Month 2
Metabolomic Profile
Time frame: Day 0, Month 2 (post-training)
Cross sectional area measurement
Time frame: Day 0, Month 2 (post-training)
Capillary to fibre ratio.
Time frame: Day 0, Month 2 (post-training)
Satellite cell number
Time frame: Day 0, Month 2 (post-training)
Neuromuscular activation
Time frame: Day 0, Month 2 (post-training)
Quadriceps muscular Oxygen Tissue Saturation
Time frame: Day 0, Month 2 (post-training)
O2 uptake Efficiency during walk test
Time frame: Day 0, Month 2 (post-training)
Creatine Kinase (CPK)
Time frame: Day 0
Creatine Kinase (CPK)
Time frame: Day 7 (post-training)
Creatine Kinase (CPK)
Time frame: Month 2 (post-training)
C-reactive protein (CRP)
Time frame: Day 0
C-reactive protein (CRP)
Time frame: Day 7 (post-training)
C-reactive protein (CRP)
Time frame: Month 2 (post-training)

Results and safety

The study was stopped early (reason given: Stop premature due to futility). Results are not available in the source record.

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 5 Aug 2026.
Background: PubMed 32128276Zhang P, Li J, Liu H, Han N, Ju J, Kou Y, Chen L, Jiang M, Pan F, Zheng Y, Gao Z, Jiang B. Long-term bone and lung consequences associated with hospital-acquired severe acute respiratory syndrome: a 15-year follow-up from a prospective cohort study. Bone Res. 2020 Feb 14;8:8. doi: 10.1038/s41413-020-0084-5. eCollection 2020.
Background: PubMed 24108501Puthucheary ZA, Rawal J, McPhail M, Connolly B, Ratnayake G, Chan P, Hopkinson NS, Phadke R, Dew T, Sidhu PS, Velloso C, Seymour J, Agley CC, Selby A, Limb M, Edwards LM, Smith K, Rowlerson A, Rennie MJ, Moxham J, Harridge SD, Hart N, Montgomery HE. Acute skeletal muscle wasting in critical illness. JAMA. 2013 Oct 16;310(15):1591-600. doi: 10.1001/jama.2013.278481.
Background: PubMed 27891297Connolly B, Salisbury L, O'Neill B, Geneen L, Douiri A, Grocott MP, Hart N, Walsh TS, Blackwood B. Exercise rehabilitation following intensive care unit discharge for recovery from critical illness: executive summary of a Cochrane Collaboration systematic review. J Cachexia Sarcopenia Muscle. 2016 Dec;7(5):520-526. doi: 10.1002/jcsm.12146. Epub 2016 Sep 16.
Background: PubMed 31752979van Zanten ARH, De Waele E, Wischmeyer PE. Nutrition therapy and critical illness: practical guidance for the ICU, post-ICU, and long-term convalescence phases. Crit Care. 2019 Nov 21;23(1):368. doi: 10.1186/s13054-019-2657-5.
Background: PubMed 32240762Wu Y, Xu X, Chen Z, Duan J, Hashimoto K, Yang L, Liu C, Yang C. Nervous system involvement after infection with COVID-19 and other coronaviruses. Brain Behav Immun. 2020 Jul;87:18-22. doi: 10.1016/j.bbi.2020.03.031. Epub 2020 Mar 30.
Background: PubMed 17133183Bailey P, Thomsen GE, Spuhler VJ, Blair R, Jewkes J, Bezdjian L, Veale K, Rodriquez L, Hopkins RO. Early activity is feasible and safe in respiratory failure patients. Crit Care Med. 2007 Jan;35(1):139-45. doi: 10.1097/01.CCM.0000251130.69568.87.
Background: PubMed 18840842Needham DM. Mobilizing patients in the intensive care unit: improving neuromuscular weakness and physical function. JAMA. 2008 Oct 8;300(14):1685-90. doi: 10.1001/jama.300.14.1685.
Results publication: PubMed 42019312Cormier C, Lanhers C, Rannou F, Grolier M, Pelletier Visa M, Feasson L, Ornetti P, Gouteron A, Richard R, Costes F, Pereira B, Coudeyre E. Impact of eccentric exercise on walking functional capacity after severe COVID-19: randomized, controlled open-label trial. Ann Phys Rehabil Med. 2026 Jun;69(5):102125. doi: 10.1016/j.rehab.2026.102125. Epub 2026 Apr 20.

Related trials for Covid19

Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Active, not recruitingPhase 1
A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults
COVID-19
Active, not recruiting
Intervention to Address Disparate Mental Health Consequences of COVID-19 Pandemic on Latinx and African Newcomers
Mental Health Issue, Mental Health Disorder
Recruiting
Home-Based Exercise Tele-Rehabilitation After COVID-19
Post SARS-CoV2 (COVID-19)
Not yet recruitingPhase 1
A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 Vaccine
COVID -19

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.

Maxime GROLIER, MD, MSc principal investigator

University Hospital, Clermont-Ferrand

Emmanuel COUDEYRE, MD, PhD study director

University Hospital, Clermont-Ferrand

3 sites in 1 country: see every site and its status.

Questions about this trial

What is this clinical trial studying?

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 5 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 3 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study was stopped early (reason given: Stop premature due to futility). Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Functional walking capacity (time frame: Day 0, Month 1, Month 2 and Month 6). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04649086, which also lists 8 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Aug 2026.